JOST
16.5.2023 10:01:27 CEST | Business Wire | Press release
In April 2021 JOST introduced the revolutionary KKS automatic coupling system. It enables the driver to couple and uncouple the semi-trailer via remote control – automatically, safely and quickly. Climbing out of the cabin, cranking down the landing gear and manually connecting the spiral cable, air and brake connections are all a thing of the past. Now JOST presents the latest development of the KKS: the KKS-U Connector which is retrofittable to existing trailers that already are on the roads of this world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005001/en/
The KKS-U Connector is easily retrofittable to trailers that are already in use. (Photo: JOST)
Coupling and uncoupling a trailer is still a lengthy, expensive and hazardous procedure. The truck driver has to be aware of many different things, each of which are time-consuming and pose a hazard to health and safety. As the global market leader for fifth wheel couplings and landing gears, JOST is providing a smart solution for the future of coupling with its KKS automatic coupling system. The KKS 42 fifth wheel coupling, Modul E-Drive electric landing gear, sensor coupling system, 3-sensors, LubeTronic automatic lubrication system, KKS remote control and the ISO 13044-2-certified KKS connector all combine to form an innovative system for the coupling process.
KKS-U Connector retrofittable to existing trailers
Until now the KKS was a solution for mixed fleets and new trailers. JOST has now further developed the system and is introducing the new KKS-U Connector to the market. Fitted to the underside of the trailer, the KKS-U Connector is an alternative installation variant and enables fleet operators to equip existing trailers easily with the KKS. It connects all the mechanical, electric, and air connections between the truck and trailer, eliminating the need for the standard vulnerable air, electrics and ABS/EBS spiral lines.
The KKS-U basically consists of three parts: the reliable future-proof and ISO 13044-2 compliant standard wedge, the steel spring and the cable box. The newly designed wedge has the familiar KKS connector installed inside. It is attached to the high-quality JOST king pin and rotates around it when cornering. The steel spring encases the supply lines for air, brake and electric safely and reliably. The supply lines are safely stowed in the KKS cable box and are fed into the steel spring when cornering.
“The KKS-U Connector is a unique solution for all trailers that are already in operation. Due to a particularly straightforward installation, they can be effortlessly equipped with the KKS system. No modifications to the trailer chassis are necessary”, said Andreas Jakubin, Product Manager KKS. “Thus, the KKS-U contributes to further savings in time and expenses as well as avoidance of accidents.”
Advantages of the KKS: more efficiency and safety for truck drivers
Using the KKS automatic coupling system can cut the time required to change a trailer by up to 50 percent, as there is no need to manually crank the landing gear, connect the supply lines or open the fifth wheel coupling. The KKS significantly reduces the total costs for each circuit, with savings of up to 50 percent possible during the coupling and uncoupling process. It is particularly well suited for transport companies which perform coupling processes often and drive short distances, such as those in on-site transport, as the time saved here really pays off financially. Another application is the transport of goods where safety plays a key role, such as hazardous goods, as the sensor monitoring guarantees a high level of security against trailer losses and incorrect coupling. The KKS is also an ideal solution for transport between production sites and logistics facilities. Errors or damage caused during the coupling process are eliminated completely thanks to monitoring through the KKS remote control. For example, the Modul E-Drive landing gear is always fully retracted automatically. Moreover, the KKS reduces the probability of trailer losses due to erroneous operation, damage and occupational accidents to virtually zero.
Furthermore, the KKS makes all the physically demanding tasks of the coupling process a thing of the past, as well as ensuring that this process is no longer dependent on the weather or time of day and significantly reducing stress. A standard pneumatic cylinder opens the fifth wheel coupling effortlessly, even when the tractor-trailer is twisted. The automatic coupling process means that the driver does not have to climb in and out of the cab as often, nor climb onto the catwalk between truck and semi-trailer – two factors that significantly reduce the potential for injury. These benefits mean the KKS opens new possibilities for a more diverse driver pool; as such, JOST is providing an answer to demographic change and the lack of specialist workers.
More information on the KKS and KKS-U Connector online at: kks-futurenow.com
About JOST:
JOST is a world-leading producer and supplier of safety-critical systems for the commercial vehicle industry. Under the umbrella brand of JOST, the comprehensive range of products is broken down into systems for applications on the road and in agriculture:
The JOST brand includes fifth wheel couplings, landing gears, ball bearing turntables, king pins and container locks as well as components for alternating systems. Truck and trailer axles are also sold under the JOST brand. The tradition-steeped ROCKINGER brand comprises the core components of towing hitches, drawbar eyes and drawbars for transporters and trucks. TRIDEC offers steering systems and axle suspensions for trailers.
ROCKINGER products are also used in agricultural applications. Quicke has been part of the JOST family since February 2020 and specialises in agricultural front loaders and equipment.
JOST currently employs over 3,600 staff worldwide and has sales and production sites in over 20 countries and on all five continents. JOST has been listed on the Frankfurt Stock Exchange. Further information on JOST can be found here: www.jost-world.com
Press images can be found here: https://www.jost-world.com/en/corporate/mediacenter/press-releases.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
